Cargando…

Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening

BACKGROUND: To identify the performance of fetal Down syndrome (DS) screening for developing countries. METHODS: A prospective study on MSS (maternal serum screening) with complete follow-ups (n = 41,924) was conducted in 32 network hospitals in the northern part of Thailand. Various models of MSS w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanapirak, Chanane, Piyamongkol, Wirawit, Sirichotiyakul, Supatra, Tongprasert, Fuanglada, Srisupundit, Kasemsri, Luewan, Suchaya, Traisrisilp, Kuntharee, Jatavan, Phudit, Tongsong, Theera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880541/
https://www.ncbi.nlm.nih.gov/pubmed/31775842
http://dx.doi.org/10.1186/s12913-019-4446-x
_version_ 1783473780604010496
author Wanapirak, Chanane
Piyamongkol, Wirawit
Sirichotiyakul, Supatra
Tongprasert, Fuanglada
Srisupundit, Kasemsri
Luewan, Suchaya
Traisrisilp, Kuntharee
Jatavan, Phudit
Tongsong, Theera
author_facet Wanapirak, Chanane
Piyamongkol, Wirawit
Sirichotiyakul, Supatra
Tongprasert, Fuanglada
Srisupundit, Kasemsri
Luewan, Suchaya
Traisrisilp, Kuntharee
Jatavan, Phudit
Tongsong, Theera
author_sort Wanapirak, Chanane
collection PubMed
description BACKGROUND: To identify the performance of fetal Down syndrome (DS) screening for developing countries. METHODS: A prospective study on MSS (maternal serum screening) with complete follow-ups (n = 41,924) was conducted in 32 network hospitals in the northern part of Thailand. Various models of MSS were tested for performance. RESULTS: MSS based on Caucasian reference range resulted in very high false positive rate (FPR; 13%) in our country, compared to the rate of 7.8% with our own (Thai) reference range, whereas the detection rate was comparable. As individual screening, C-S (contingent first trimester screening including PAPP-A, and free beta-hCG, classified as a) high risk [> 1:30], indicated for invasive diagnosis; b) intermediate risk [1:30–1500], indicated for STS; and c) low risk [< 1:1500], need no further tests.) was the most effective model (sensitivity 84.9%, FPR 7.7%) but nearly one-third needed the second trimester test (STS) because of intermediate results. Additionally, about one-third had their first visits in the second trimester and had no chance of FTS (first trimester screening). C-S plus STS had a sensitivity of 82.4% and FPR 8.1% whereas independent first and second trimester screening model (I-S) gave the sensitivity of 78.4% and FPR of 7.5% but was much more convenient and practical. CONCLUSION: C-S plus STS was the most effective models while I-S model was also effective and may be better for developing countries because of its simplicity and feasibility.
format Online
Article
Text
id pubmed-6880541
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68805412019-11-29 Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening Wanapirak, Chanane Piyamongkol, Wirawit Sirichotiyakul, Supatra Tongprasert, Fuanglada Srisupundit, Kasemsri Luewan, Suchaya Traisrisilp, Kuntharee Jatavan, Phudit Tongsong, Theera BMC Health Serv Res Research Article BACKGROUND: To identify the performance of fetal Down syndrome (DS) screening for developing countries. METHODS: A prospective study on MSS (maternal serum screening) with complete follow-ups (n = 41,924) was conducted in 32 network hospitals in the northern part of Thailand. Various models of MSS were tested for performance. RESULTS: MSS based on Caucasian reference range resulted in very high false positive rate (FPR; 13%) in our country, compared to the rate of 7.8% with our own (Thai) reference range, whereas the detection rate was comparable. As individual screening, C-S (contingent first trimester screening including PAPP-A, and free beta-hCG, classified as a) high risk [> 1:30], indicated for invasive diagnosis; b) intermediate risk [1:30–1500], indicated for STS; and c) low risk [< 1:1500], need no further tests.) was the most effective model (sensitivity 84.9%, FPR 7.7%) but nearly one-third needed the second trimester test (STS) because of intermediate results. Additionally, about one-third had their first visits in the second trimester and had no chance of FTS (first trimester screening). C-S plus STS had a sensitivity of 82.4% and FPR 8.1% whereas independent first and second trimester screening model (I-S) gave the sensitivity of 78.4% and FPR of 7.5% but was much more convenient and practical. CONCLUSION: C-S plus STS was the most effective models while I-S model was also effective and may be better for developing countries because of its simplicity and feasibility. BioMed Central 2019-11-27 /pmc/articles/PMC6880541/ /pubmed/31775842 http://dx.doi.org/10.1186/s12913-019-4446-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wanapirak, Chanane
Piyamongkol, Wirawit
Sirichotiyakul, Supatra
Tongprasert, Fuanglada
Srisupundit, Kasemsri
Luewan, Suchaya
Traisrisilp, Kuntharee
Jatavan, Phudit
Tongsong, Theera
Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
title Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
title_full Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
title_fullStr Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
title_full_unstemmed Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
title_short Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening
title_sort fetal down syndrome screening models for developing countries; part i: performance of maternal serum screening
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880541/
https://www.ncbi.nlm.nih.gov/pubmed/31775842
http://dx.doi.org/10.1186/s12913-019-4446-x
work_keys_str_mv AT wanapirakchanane fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening
AT piyamongkolwirawit fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening
AT sirichotiyakulsupatra fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening
AT tongprasertfuanglada fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening
AT srisupunditkasemsri fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening
AT luewansuchaya fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening
AT traisrisilpkuntharee fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening
AT jatavanphudit fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening
AT tongsongtheera fetaldownsyndromescreeningmodelsfordevelopingcountriespartiperformanceofmaternalserumscreening